Drugs / Lexaptepid pegol
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT01522794 | Jan → Mar 2012 | anemia due to chronic disorder | TME Pharma AG | Completed | Met primary |
| Phase 1 | NCT01372137 | Jul 2011 → Mar 2012 | anemia | TME Pharma AG | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02079896 | May 2014 → Nov 2015 | anemia, end stage renal failure | TME Pharma AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01691040 | Sep 2012 → Nov 2013 | anemia due to chronic disorder | TME Pharma AG | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lexaptepid pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02079896 ↗ |
| Known as | NOX-H94 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01372137 ↗ |
| Action | Inhibit | “Antagonism of hepcidin by NOX-H94 therefore leads to elevated levels of iron” NCT01372137 ↗ |
| Modality | Oligonucleotide (other) | “NOX-H94 25 mg (oligonucleotide basis)” NCT01372137 ↗ |
| Route | Intravenous | “Route: IV infusion over 15 minutes / SC administration” NCT01372137 ↗ |
| Route | Subcutaneous | “Route: IV infusion over 15 minutes / SC administration” NCT01372137 ↗ |